Zentalis Pharmaceuticals (ZNTL) Earnings Analysis

Zentalis Pharmaceuticals (ZNTL) has no confirmed upcoming earnings date. Last quarter (2026-03-26) it missed with EPS -0.49 USD vs -0.41 USD est (-19.5%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.60.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ZNTL next report earnings?

No confirmed upcoming earnings date is currently scheduled for ZNTL. This page updates as the calendar is published.

ZNTL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-26-0.49 USD-0.41 USD-19.5%Miss
2025-11-10-0.37 USD-0.49 USD+24.5%Beat
2025-05-14-0.67 USD-0.67 USD0%Beat
2024-08-09-1.24 USD-0.83 USD-49.4%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

ZNTL valuation and analyst view

Trailing P/E-2.60
Trailing EPS-1.76667 USD
Price / book1.73
Dividend yield0.00%
Market cap0.31B
Analyst consensusBuy (8 buy / 4 hold / 0 sell)
Avg price target10 USD

Related research pages

Frequently asked questions

When is Zentalis Pharmaceuticals (ZNTL)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for ZNTL. This page updates as the calendar is published.

Did ZNTL beat earnings last quarter?

In its 2026-03-26 report, ZNTL posted EPS of -0.49 USD versus a -0.41 USD estimate — a miss of 19.5%.

What is ZNTL's earnings track record?

Over the last 4 reported quarters with consensus data, ZNTL beat estimates 2 times (50%).

What is ZNTL's current P/E ratio and EPS?

ZNTL trades at a trailing P/E of -2.60 on trailing EPS of -1.7666657178640555 USD.

What do analysts rate ZNTL?

Analyst consensus is "Buy" across 12 ratings (0 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 10 USD.